The establishment of EVISA is funded by the EU through
the Fifth Framework Programme (G7RT- CT- 2002- 05112).
Supporters of EVISA includes:
Glossary
satraplatin
An orally administered third generation platinum compound with potential antineoplastic activity. Satraplatin
forms highly reactive, charged, platinum complexes which bind to
nucleophilic groups in DNA, inducing intrastrand and interstrand DNA
cross-links, as well as DNA-protein cross-links. These cross-links
result in cell growth inhibition and apoptosis.
The term "satraplatin" was found in the following pages: